RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.
Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
人表皮生长因子受体2(HER2)阳性乳腺癌具有高度转移潜能。靶向HER2的单克隆抗体(mAbs),如曲妥珠单抗和帕妥珠单抗,是HER2阳性乳腺癌辅助治疗的基石。越来越多的临床前和临床证据表明,由抗体依赖性细胞介导的细胞毒性(ADCC)介导的先天免疫在mAbs对由此产生的抗肿瘤反应的临床效果中具有重要作用。在这篇综述中,我们概述了自然杀伤(NK)细胞和ADCC在HER2阳性乳腺癌靶向治疗中的作用,包括NK细胞的生物学功能以及NK细胞和ADCC在抗HER2靶向药物中的作用。然后,我们讨论了调控机制以及利用我们对NK细胞和ADCC的认识作为HER2阳性乳腺癌免疫治疗方法的最新策略。
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer has a high metastatic potential. Monoclonal antibodies (mAbs) that target HER2, such as trastuzumab and pertuzumab, are the cornerstone of adjuvant therapy for HER2-positive breast cancer.
A growing body of preclinical and clinical evidence points to the importance of innate immunity mediated by antibody-dependent cellular cytotoxicity (ADCC) in the clinical effect of mAbs on the resulting anti-tumor response. In this review, we provide an overview of the role of natural killer (NK) cells and ADCC in targeted therapy of HER2-positive breast cancer, including the biological functions of NK cells and the role of NK cells and ADCC in anti-HER2 targeted drugs.
We then discuss regulatory mechanisms and recent strategies to leverage our knowledge of NK cells and ADCC as an immunotherapy approach for HER2-positive breast cancer.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。